Fri, Sep 19, 2014, 3:23 PM EDT - U.S. Markets close in 37 mins.

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • bionerd51 bionerd51 Apr 16, 2013 9:51 AM Flag

    Bottom Line...

    No one should have expected an approval yesterday. SRPT was looking for guidance from the FDA on if/how to apply for AA. The FDA gave them guidance WITHOUT delaying the expected AA approval timeframe. How is it that many here are concluding that this is bad news? That's ridiculous. The FDA is basically stating that they will decide AA on the current PhaseII trial. Isn't that the best case scenario that all longs have been hoping for? Asking for additional safety data and support for dystrophin as a surrogate marker for Duchennes is a home run. The only negative is that our "CEO of the Year" [give me a break] didnot come prepared to the FDA meeting. He should have been prepared with NDA quality/quantity comprehensive data and he wasn't. FDA's queries are about as positive as I've seen in AA at the post-PhaseII FDA meet.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SRPT
21.61-0.92(-4.08%)3:22 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.